Insider · CIK 0002044770
Katherine Goodrich
Files at TARS (Tarsus Pharmaceuticals, Inc.). First filing Jun 17, 2026, latest Jun 17, 2026.
In brief
Katherine Goodrich files SEC Form 4 as director at TARS (Tarsus Pharmaceuticals, Inc.). Since Jun 17, 2026, Katherine Goodrich has reported 0 open-market buys worth $0 and 1 open-market sell worth $183k, the latest filed on Jun 17, 2026.
A track record needs three past buys with six months of prices behind them; Katherine Goodrich has 0, so none is measured yet.
The newest scored trade: sold $183k of TARS on Jun 15, 2026, filed Jun 17, 2026, scored 42 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $183k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TARS: Tarsus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Tarsus Pharmaceuticals, Inc. | $183k 2,954 shares | -57% | +59% from low-25% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 2,954 0.01% of outstanding | $183k | Jun 15, 2026 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +3,837 | $0.00 | $0 | 3,837 | Jun 29, 2026 |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +2,417 | $0.00 | $0 | 2,417 | Jun 29, 2026 |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -2,954 | $62.08 | $183k | 2,233 | Jun 17, 2026 |
| Jun 12, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +2,954 | - | - | 5,187 | Jun 16, 2026 |
| Jun 12, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,954 | $0.00 | $0 | 0 | Jun 16, 2026 |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +2,233 | - | - | 2,233 | Jan 14, 2026 |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,233 | $0.00 | $0 | 4,467 | Jan 14, 2026 |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +4,540 | $0.00 | $0 | 4,540 | Jun 16, 2025 |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +2,954 | $0.00 | $0 | 2,954 | Jun 16, 2025 |
| Nov 13, 2024 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 15, 2024 |
| Nov 13, 2024 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +6,700 | $0.00 | $0 | 6,700 | Nov 15, 2024 |
Questions about Katherine Goodrich
Answered from the filings on this page, as of the latest one.
Is Katherine Goodrich buying or selling?
In the last 12 months Katherine Goodrich reported 0 open-market buys worth $0 and 1 open-market sell worth $183k on SEC Form 4; the latest was sold $183k of TARS on Jun 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Katherine Goodrich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Katherine Goodrich has 0.
Where does Katherine Goodrich file Form 4?
Katherine Goodrich has filed Form 4 at TARS (Tarsus Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.